bluebird bio Stock Price, News & Analysis (NASDAQ:BLUE)

$206.05 +4.85 (+2.41 %)
(As of 02/25/2018 04:00 PM ET)
Previous Close$206.05
Today's Range$195.05 - $206.65
52-Week Range$74.45 - $222.03
Volume424,838 shs
Average Volume932,514 shs
Market Capitalization$10.30 billion
P/E Ratio-26.93
Dividend YieldN/A
Beta2.07

About bluebird bio (NASDAQ:BLUE)

bluebird bio logobluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:BLUE
CUSIPN/A
Phone+1-339-4999300

Debt

Debt-to-Equity RatioN/A
Current Ratio13.84%
Quick Ratio9.88%

Price-To-Earnings

Trailing P/E Ratio-26.9346405228758
Forward P/E Ratio-27.84
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.43 million
Price / Sales290.67
Cash FlowN/A
Price / CashN/A
Book Value$32.48 per share
Price / Book6.34

Profitability

Trailing EPS($7.65)
Net Income$-263,500,000.00
Net Margins-947.42%
Return on Equity-28.09%
Return on Assets-23.00%

Miscellaneous

Employees328
Outstanding Shares49,980,000

bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

How were bluebird bio's earnings last quarter?

bluebird bio Inc (NASDAQ:BLUE) announced its earnings results on Wednesday, February, 21st. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.68) by $0.84. The biotechnology company had revenue of $4.17 million for the quarter, compared to analysts' expectations of $7.11 million. bluebird bio had a negative return on equity of 28.09% and a negative net margin of 947.42%. The firm's revenue was up 169.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.88) earnings per share. View bluebird bio's Earnings History.

When will bluebird bio make its next earnings announcement?

bluebird bio is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for bluebird bio.

Where is bluebird bio's stock going? Where will bluebird bio's stock price be in 2018?

21 brokers have issued twelve-month price targets for bluebird bio's shares. Their forecasts range from $102.00 to $250.00. On average, they anticipate bluebird bio's stock price to reach $181.78 in the next year. View Analyst Ratings for bluebird bio.

What are Wall Street analysts saying about bluebird bio stock?

Here are some recent quotes from research analysts about bluebird bio stock:

  • 1. Maxim Group analysts commented, "bluebird reported YE-2017 with $22M in revenue (collaborative/licensing revenue) and a net loss of $336M. Operating expenses have increased as clinical programs advance to later stages of development. The company ended the period with $1.6B in cash, sufficient runway into 2021 at the current burn rate." (2/22/2018)
  • 2. Cantor Fitzgerald analysts commented, "Lining Up for Three Marketing Applications. bluebird plans to file for European approval of LentiGlobin in transfusion-dependent b-thalassemia (non-b0/b0) in 2H18, followed by bb2121 in relapsed/refractory multiple myeloma and Lenti-D in cerebral adrenoleukodystrophy in 2019. As a reminder, bb2121 is being investigated in a Phase 3 study, KarMMa, which is being conducted by bluebird’s bb2121 development partner, Celgene (CELG – Neutral, covered by Mara Goldstein)." (2/21/2018)
  • 3. Morgan Stanley analysts commented, "excitement." But now may be a time for investors to turn cautious, at least according to analysts at Morgan Stanley. The firm's Matthew Harrison downgraded Bluebird's stock rating from Equal Weight to Underweight with an unchanged $105 price target.Heading into the end of 2017 there are underappreciated risks that the Street may be ignoring, Harrison commented. Specifically, data related to LentiGlobin sickle cell data is unlikely to show any significant improvement in hemoglobin production that will be good enough to "increase investor confidence" in its sickle cell gene therapy."Based on prior data, our premise is that to improve hemoglobin production in sickle cell patients, the correlation between drug-product vector copy number (DP VCN) and peripheral VCN (pVCN) needs to increase substantially," the analyst explained. "We do not believe the evidence supports current investor optimism that this can be solved by ASH." (10/2/2017)
  • 4. According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (7/18/2017)

Who are some of bluebird bio's key competitors?

Who are bluebird bio's key executives?

bluebird bio's management team includes the folowing people:

  • Daniel S. Lynch, Independent Chairman of the Board (Age 59)
  • Nick Leschly, President, Chief Executive Officer, Director (Age 44)
  • Jeffrey T. Walsh, Chief Financial Officer, Principal Financial Officer and Strategy Officer (Age 51)
  • Susanna Gatti High, Chief Operating Officer (Age 49)
  • Kory J. Wentworth, Principal Accounting Officer, Vice President - Finance (Age 39)
  • Philip D. Gregory Ph.D., Chief Scientific Officer (Age 46)
  • David M. Davidson M.D., Chief Medical Officer (Age 53)
  • Jason F. Cole Esq., Chief Legal Officer, Secretary (Age 44)
  • John O. Agwunobi M.D., Director (Age 52)
  • Mary Lynne Hedley Ph.D., Director (Age 54)

Who owns bluebird bio stock?

bluebird bio's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.81%), OppenheimerFunds Inc. (1.96%), Franklin Resources Inc. (1.40%), Victory Capital Management Inc. (1.35%), Jennison Associates LLC (1.10%) and Two Sigma Advisers LP (0.94%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Institutional Ownership Trends for bluebird bio.

Who sold bluebird bio stock? Who is selling bluebird bio stock?

bluebird bio's stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, UBS Asset Management Americas Inc., ArrowMark Colorado Holdings LLC, Jennison Associates LLC, Victory Capital Management Inc., Emerald Advisers Inc. PA, Frontier Capital Management Co. LLC and Quantitative Investment Management LLC. Company insiders that have sold bluebird bio company stock in the last year include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Insider Buying and Selling for bluebird bio.

Who bought bluebird bio stock? Who is buying bluebird bio stock?

bluebird bio's stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Redmile Group LLC, BlackRock Inc., Franklin Resources Inc., Carillon Tower Advisers Inc., Element Capital Management LLC, Masters Capital Management LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for bluebird bio.

How do I buy bluebird bio stock?

Shares of bluebird bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is bluebird bio's stock price today?

One share of bluebird bio stock can currently be purchased for approximately $206.05.

How big of a company is bluebird bio?

bluebird bio has a market capitalization of $10.30 billion and generates $35.43 million in revenue each year. The biotechnology company earns $-263,500,000.00 in net income (profit) each year or ($7.65) on an earnings per share basis. bluebird bio employs 328 workers across the globe.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 Binney St, CAMBRIDGE, MA 02142-1512, United States. The biotechnology company can be reached via phone at +1-339-4999300 or via email at [email protected]


MarketBeat Community Rating for bluebird bio (BLUE)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  654 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  919
MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

bluebird bio (NASDAQ:BLUE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyHold
Consensus Rating Score: 2.482.452.572.47
Ratings Breakdown: 2 Sell Rating(s)
7 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
8 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $181.78$161.21$131.70$99.72
Price Target Upside: 12.35% downside22.29% downside19.30% downside2.70% upside

bluebird bio (NASDAQ:BLUE) Consensus Price Target History

Price Target History for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ:BLUE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/22/2018Maxim GroupReiterated RatingHold$200.00MediumView Rating Details
2/22/2018Bank of AmericaBoost Price TargetNeutral -> Neutral$185.00 -> $218.00MediumView Rating Details
2/22/2018BMO Capital MarketsSet Price TargetOutperform -> Buy$215.00 -> $222.00HighView Rating Details
2/22/2018Sanford C. BernsteinReiterated RatingHold$153.00 -> $211.00HighView Rating Details
2/22/2018Cantor FitzgeraldLower Price TargetUnderweight$122.00 -> $113.00HighView Rating Details
2/1/2018Canaccord GenuityReiterated RatingBuy$250.00HighView Rating Details
1/25/2018Leerink SwannDowngradeOutperform -> Market Perform$162.00 -> $194.00LowView Rating Details
1/9/2018OppenheimerReiterated RatingHoldLowView Rating Details
12/21/2017CIBCInitiated CoverageMarket Perform -> Market PerformHighView Rating Details
12/13/2017BarclaysReiterated RatingOverweight -> Overweight$162.00 -> $209.00HighView Rating Details
12/12/2017SunTrust BanksBoost Price TargetBuy$223.00HighView Rating Details
12/12/2017Wells Fargo & CoReiterated RatingOutperform$190.00 -> $242.00HighView Rating Details
12/11/2017Jefferies GroupUpgradeHold -> Buy$130.00 -> $211.00HighView Rating Details
11/3/2017Morgan StanleyUpgradeUnderweight -> Equal WeightN/AView Rating Details
11/2/2017WedbushReiterated RatingOutperform$135.00 -> $174.00N/AView Rating Details
11/2/2017BTIG ResearchUpgradeNeutral -> Buy$177.00N/AView Rating Details
10/16/2017Evercore ISIUpgradeIn-Line -> Outperform$102.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingBuy -> Buy$186.00N/AView Rating Details
8/31/2017CowenReiterated RatingOutperformHighView Rating Details
6/26/2017Janney Montgomery ScottSet Price TargetBuy$125.00N/AView Rating Details
6/16/2017Standpoint ResearchReiterated RatingBuy -> Reduce$110.00LowView Rating Details
2/23/2017Roth CapitalSet Price TargetHold$71.00N/AView Rating Details
12/7/2016JPMorgan Chase & Co.Reiterated RatingBuy$120.00N/AView Rating Details
11/30/2016Piper Jaffray CompaniesReiterated RatingOverweight$95.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

bluebird bio (NASDAQ:BLUE) Earnings History and Estimates Chart

Earnings by Quarter for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ BLUE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018($2.01)N/AView Earnings Details
2/21/2018Q4 2017($1.68)($2.52)$7.11 million$4.17 millionViewN/AView Earnings Details
11/1/2017Q3 2017($1.68)($1.73)$8.47 million$7.71 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.66)($1.73)$6.29 million$16.70 millionViewN/AView Earnings Details
5/3/2017Q1 2017($1.76)($1.68)$1.51 million$6.83 millionViewN/AView Earnings Details
2/22/2017Q4 2016($1.86)($1.88)$1.76 million$1.55 millionViewN/AView Earnings Details
11/2/2016Q3 2016($1.59)($2.07)$1.82 million$1.55 millionViewN/AView Earnings Details
8/3/2016Q2($1.44)($1.59)$2.01 million$1.55 millionViewN/AView Earnings Details
5/4/2016Q1($1.23)($1.52)$4.50 million$1.50 millionViewN/AView Earnings Details
2/24/2016Q4($1.11)($1.29)$3.21 million$1.47 millionViewN/AView Earnings Details
11/4/2015Q3($0.96)($1.18)$5.63 million$1.30 millionViewListenView Earnings Details
8/6/2015Q215($0.78)($1.57)$8.60 million$4.94 millionViewN/AView Earnings Details
5/6/2015Q115($0.68)($0.76)$6.20 million$6.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.62)($0.66)$6.20 million$6.30 millionViewN/AView Earnings Details
11/12/2014Q314($0.52)($0.61)$6.20 million$6.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.45)($0.06)$6.15 million$6.30 millionViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.44)$6.23 million$6.30 millionViewN/AView Earnings Details
3/5/2014($0.31)($0.34)$6.20 million$6.34 millionViewN/AView Earnings Details
11/12/2013Q3($0.25)($0.26)$5.59 million$6.39 millionViewN/AView Earnings Details
8/8/2013Q213($0.35)($2.13)$4.85 million$6.30 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

bluebird bio (NASDAQ:BLUE) Earnings Estimates

2018 EPS Consensus Estimate: ($8.04)
2019 EPS Consensus Estimate: ($8.81)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($2.26)($1.68)($1.98)
Q2 20183($2.16)($1.66)($1.97)
Q3 20183($2.18)($1.73)($2.02)
Q4 20183($2.23)($1.76)($2.06)
Q1 20191($2.31)($2.31)($2.31)
Q2 20191($2.45)($2.45)($2.45)
Q3 20191($2.07)($2.07)($2.07)
Q4 20191($1.98)($1.98)($1.98)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for bluebird bio (NASDAQ:BLUE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

bluebird bio (NASDAQ BLUE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Insider Trades by Quarter for bluebird bio (NASDAQ:BLUE)
Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ BLUE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/2/2018David DavidsonInsiderSell4,000$202.36$809,440.00View SEC Filing  
1/30/2018Jason ColeInsiderSell25,000$195.91$4,897,750.0044,798View SEC Filing  
1/30/2018Susanna Gatti HighCOOSell17,262$195.91$3,381,798.4228,512View SEC Filing  
1/8/2018David DavidsonInsiderSell3,522$173.61$611,454.4213,959View SEC Filing  
1/5/2018Jason ColeInsiderSell1,129$173.38$195,746.0219,945View SEC Filing  
1/5/2018Nick LeschlyCEOSell5,435$173.38$942,320.30171,009View SEC Filing  
1/3/2018David DavidsonInsiderSell6,000$180.30$1,081,800.0021,977View SEC Filing  
12/13/2017Nick LeschlyInsiderSell117,500$184.08$21,629,400.00293,232View SEC Filing  
12/11/2017Jeffrey T WalshInsiderSell9,900$216.54$2,143,746.0037,205View SEC Filing  
12/11/2017Mark VachonDirectorSell7,000$216.64$1,516,480.008,000View SEC Filing  
12/1/2017Philip D GregoryInsiderSell2,250$172.54$388,215.0028,734View SEC Filing  
12/1/2017Susanna Gatti HighCOOSell1,282$172.15$220,696.3013,718View SEC Filing  
11/10/2017Jeffrey T WalshInsiderSell9,900$149.58$1,480,842.0028,798View SEC Filing  
11/1/2017Jeffrey T WalshInsiderSell35,000$151.38$5,298,300.0062,305View SEC Filing  
11/1/2017Nick LeschlyCEOSell2,127$145.17$308,776.59257,486View SEC Filing  
10/23/2017Nick LeschlyInsiderSell7,050$145.14$1,023,237.00259,059View SEC Filing  
10/20/2017Nick LeschlyCEOSell3,350$145.02$485,817.00259,059View SEC Filing  
10/17/2017Nick LeschlyCEOSell10,823$145.05$1,569,876.15262,409View SEC Filing  
10/10/2017Jeffrey T WalshInsiderSell4,900$129.94$636,706.00View SEC Filing  
10/2/2017David DavidsonInsiderSell4,000$131.31$525,240.00View SEC Filing  
9/14/2017John MaraganoreDirectorSell18,868$131.21$2,475,670.2824,711View SEC Filing  
9/12/2017Mark VachonDirectorSell6,000$126.82$760,920.008,000View SEC Filing  
9/11/2017Jeffrey T WalshInsiderSell4,900$125.73$616,077.0032,205View SEC Filing  
9/1/2017Nick LeschlyInsiderSell46,833$122.27$5,726,270.91289,368View SEC Filing  
8/31/2017Daniel LynchDirectorSell500$120.00$60,000.003,300View SEC Filing  
8/31/2017Jeffrey T WalshInsiderSell12,000$125.01$1,500,120.0039,305View SEC Filing  
8/30/2017Nick LeschlyInsiderSell25,667$115.18$2,956,325.06339,368View SEC Filing  
8/28/2017Jeffrey T WalshInsiderSell1,250$107.06$133,825.0028,555View SEC Filing  
8/14/2017James MandellDirectorSell1,000$95.95$95,950.001,000View SEC Filing  
8/10/2017Jeffrey T WalshInsiderSell1,250$95.41$119,262.5028,555View SEC Filing  
8/7/2017Philip D GregoryInsiderSell750$99.00$74,250.0031,234View SEC Filing  
8/4/2017Eric SullivanInsiderSell861$93.83$80,787.635,924View SEC Filing  
8/1/2017David DavidsonInsiderSell3,000$92.37$277,110.0018,977View SEC Filing  
7/10/2017Jeffrey T WalshInsiderSell2,500$99.89$249,725.0029,805View SEC Filing  
7/7/2017David DavidsonInsiderSell1,200$100.49$120,588.0016,077View SEC Filing  
7/6/2017Philip D GregoryInsiderSell2,250$103.83$233,617.5033,734View SEC Filing  
7/5/2017David DavidsonInsiderSell5,000$105.28$526,400.0022,177View SEC Filing  
6/29/2017Eric SullivanInsiderSell6,787$108.96$739,511.528,466View SEC Filing  
6/27/2017Nick LeschlyInsiderSell25,000$108.05$2,701,250.00360,656View SEC Filing  
6/23/2017Daniel LynchDirectorSell4,000$109.09$436,360.004,808View SEC Filing  
6/20/2017Daniel LynchDirectorSell2,500$120.03$300,075.005,300View SEC Filing  
6/7/2017Jason ColeInsiderSell17,245$100.22$1,728,293.9030,871View SEC Filing  
6/6/2017Daniel LynchDirectorSell2,263$100.14$226,616.823,663View SEC Filing  
6/6/2017Philip D GregoryInsiderSell1,500$99.04$148,560.0037,279View SEC Filing  
6/5/2017David DavidsonInsiderSell1,000$90.00$90,000.0018,177View SEC Filing  
5/25/2017Daniel LynchDirectorSell2,000$80.00$160,000.003,400View SEC Filing  
4/27/2017Daniel LynchDirectorSell1,000$90.01$90,010.002,400View SEC Filing  
4/25/2017Daniel LynchDirectorSell2,000$86.75$173,500.003,400View SEC Filing  
4/10/2017Jeffrey T WalshInsiderSell1,250$87.38$109,225.0028,555View SEC Filing  
4/3/2017David DavidsonInsiderSell3,000$90.89$272,670.0020,177View SEC Filing  
3/27/2017Daniel LynchDirectorSell3,000$88.12$264,360.003,400View SEC Filing  
3/16/2017Daniel LynchDirectorSell237$100.07$23,716.591,637View SEC Filing  
3/16/2017Jason ColeInsiderSell4,930$100.07$493,345.1016,981View SEC Filing  
3/3/2017John MaraganoreDirectorSell13,839$85.02$1,176,591.785,765View SEC Filing  
2/15/2017Daniel LynchDirectorSell150$80.22$12,033.001,550View SEC Filing  
2/15/2017Jason ColeInsiderSell666$80.22$53,426.5212,051View SEC Filing  
2/14/2017Daniel LynchDirectorSell850$80.01$68,008.502,250View SEC Filing  
2/14/2017Jason ColeInsiderSell3,772$80.01$301,797.7212,717View SEC Filing  
1/31/2017James MandellDirectorSell8,000$75.04$600,320.009,000View SEC Filing  
1/27/2017Daniel LynchDirectorSell1,000$70.09$70,090.002,400View SEC Filing  
1/27/2017David DavidsonInsiderSell6,000$69.02$414,120.0014,677View SEC Filing  
1/5/2017Jason ColeInsiderSell549$67.10$36,837.909,389View SEC Filing  
10/3/2016Eric SullivanInsiderSell416$67.00$27,872.005,891View SEC Filing  
9/13/2016Eric SullivanInsiderSell416$59.00$24,544.005,891View SEC Filing  
8/3/2016Eric SullivanInsiderSell416$59.00$24,544.005,891View SEC Filing  
7/27/2016Eric SullivanInsiderSell2,912$55.01$160,189.124,456View SEC Filing  
7/20/2016Eric SullivanInsiderSell2,807$45.04$126,427.284,656View SEC Filing  
7/15/2016David DavidsonInsiderSell1,000$45.08$45,080.0010,600View SEC Filing  
6/16/2016Philip D GregoryInsiderSell2,931$39.52$115,833.1230,069View SEC Filing  
6/15/2016David DavidsonInsiderSell1,000$40.11$40,110.0010,600View SEC Filing  
5/16/2016David DavidsonInsiderSell1,000$38.73$38,730.0010,600View SEC Filing  
4/15/2016David DavidsonInsiderSell1,000$49.63$49,630.0010,600View SEC Filing  
3/15/2016David DavidsonInsiderSell1,000$46.13$46,130.0010,600View SEC Filing  
2/16/2016David DavidsoninsiderSell1,000$45.18$45,180.001,000View SEC Filing  
1/15/2016David DavidsoninsiderSell1,000$44.39$44,390.00View SEC Filing  
12/15/2015David DavidsoninsiderSell1,000$58.55$58,550.00View SEC Filing  
12/8/2015Nick LeschlyCEOBuy9,682$51.75$501,043.50313,241View SEC Filing  
11/16/2015David DavidsoninsiderSell2,000$70.99$141,980.00View SEC Filing  
11/10/2015Jeffrey T. WalshCOOSell11,000$74.60$820,600.00View SEC Filing  
10/15/2015David DavidsoninsiderSell2,000$79.70$159,400.00View SEC Filing  
10/12/2015Jeffrey T. WalshCOOSell11,000$88.06$968,660.00View SEC Filing  
10/9/2015Jason ColeSVPSell5,000$86.91$434,550.00View SEC Filing  
10/5/2015Daniel LynchDirectorSell3,000$100.41$301,230.00View SEC Filing  
9/17/2015Daniel LynchDirectorSell1,500$140.06$210,090.00View SEC Filing  
9/15/2015David DavidsoninsiderSell2,000$129.98$259,960.00View SEC Filing  
9/10/2015Jeffrey T. WalshCOOSell11,000$130.02$1,430,220.00View SEC Filing  
9/9/2015Jason ColeSVPSell2,000$136.56$273,120.00View SEC Filing  
9/8/2015Daniel LynchDirectorSell7,000$132.75$929,250.00View SEC Filing  
9/8/2015Nick LeschlyCEOSell125,000$135.24$16,905,000.00246,521View SEC Filing  
9/1/2015James MandellDirectorSell1,500$125.96$188,940.00View SEC Filing  
7/20/2015Eric SullivanInsiderSell1,126$163.36$183,943.36View SEC Filing  
7/15/2015David DavidsonInsiderSell2,000$165.96$331,920.00View SEC Filing  
7/10/2015Jeffrey T WalshCOOSell11,000$158.63$1,744,930.00View SEC Filing  
7/9/2015Jason ColeSVPSell5,000$158.19$790,950.00View SEC Filing  
6/15/2015David DavidsonInsiderSell2,000$183.34$366,680.00View SEC Filing  
6/10/2015Jeffrey T WalshCOOSell11,000$179.70$1,976,700.00View SEC Filing  
6/1/2015Mitchell H FinerInsiderSell15,000$190.25$2,853,750.00View SEC Filing  
4/20/2015Mitchell H FinerInsiderSell15,000$126.03$1,890,450.00View SEC Filing  
4/15/2015David DavidsonInsiderSell2,000$130.18$260,360.00View SEC Filing  
4/10/2015Jeffrey T WalshCOOSell21,000$126.21$2,650,410.00View SEC Filing  
4/2/2015Eric SullivanInsiderSell2,998$117.81$353,194.38View SEC Filing  
3/10/2015Jeffrey T WalshCOOSell10,500$110.06$1,155,630.00View SEC Filing  
3/2/2015David DavidsonInsiderSell4,000$94.84$379,360.00View SEC Filing  
1/12/2015Jeffrey T WalshCOOSell10,500$103.57$1,087,485.00View SEC Filing  
1/2/2015David DavidsonInsiderSell4,000$90.01$360,040.00View SEC Filing  
12/19/2014John MaraganoreDirectorBuy2,352$85.00$199,920.00View SEC Filing  
12/10/2014Jeffrey T WalshCOOSell43,500$78.06$3,395,610.00View SEC Filing  
12/8/2014David DavidsonInsiderSell15,000$46.10$691,500.00View SEC Filing  
12/3/2014David DavidsonInsiderSell3,000$41.65$124,950.00View SEC Filing  
12/1/2014Mitchell H FinerInsiderSell18,000$39.70$714,600.00View SEC Filing  
12/1/2014Nick LeschlyCEOSell2,417$39.70$95,954.90View SEC Filing  
11/3/2014David DavidsonInsiderSell3,000$41.68$125,040.00View SEC Filing  
11/3/2014Nick LeschlyCEOSell25,000$41.68$1,042,000.00View SEC Filing  
10/24/2014Nick LeschlyCEOSell33,900$40.22$1,363,458.00View SEC Filing  
10/10/2014Jeffrey T WalshCOOSell7,500$33.16$248,700.00View SEC Filing  
10/9/2014Steven GillisDirectorSell115,000$35.25$4,053,750.00View SEC Filing  
10/8/2014Mitchell H FinerInsiderSell34,518$33.52$1,157,043.36View SEC Filing  
10/7/2014Steven GillisDirectorSell57,435$35.43$2,034,922.05View SEC Filing  
10/2/2014Steven GillisDirectorSell91,165$35.28$3,216,301.20View SEC Filing  
10/1/2014David DavidsonInsiderSell3,000$34.55$103,650.00View SEC Filing  
10/1/2014Nick LeschlyCEOSell8,000$34.55$276,400.00View SEC Filing  
9/12/2014Robert I TepperDirectorSell125,000$36.54$4,567,500.00View SEC Filing  
9/10/2014Jeffrey T WalshCOOSell7,500$37.02$277,650.00View SEC Filing  
9/2/2014David DavidsonInsiderSell3,000$38.00$114,000.00View SEC Filing  
9/2/2014Nick LeschlyCEOSell10,300$38.45$396,035.00View SEC Filing  
8/11/2014Jeffrey T WalshCOOSell7,500$34.26$256,950.00View SEC Filing  
8/1/2014David DavidsonInsiderSell3,000$33.62$100,860.00View SEC Filing  
8/1/2014Nick LeschlyCEOSell8,000$33.62$268,960.00View SEC Filing  
7/14/2014John MaraganoreDirectorBuy2,941$34.00$99,994.00View SEC Filing  
7/10/2014Jeffrey T WalshCOOSell7,500$33.20$249,000.00View SEC Filing  
7/3/2014Nick LeschlyCEOSell22,283$39.86$888,200.38View SEC Filing  
7/1/2014David DavidsonInsiderSell3,000$39.55$118,650.00View SEC Filing  
6/20/2014Nick LeschlyCEOSell17,075$40.06$684,024.50View SEC Filing  
6/16/2014Jeffrey T WalshCOOSell1,500$39.86$59,790.00View SEC Filing  
6/16/2014Mitchell H FinerInsiderSell10,000$39.84$398,400.00View SEC Filing  
6/16/2014Nick LeschlyCEOSell42,925$40.02$1,717,858.50View SEC Filing  
6/10/2014Jeffrey T WalshCOOSell6,000$24.23$145,380.00View SEC Filing  
6/2/2014Mitchell H FinerInsiderSell8,000$22.21$177,680.00View SEC Filing  
6/2/2014Nick LeschlyCEOSell5,000$22.21$111,050.00View SEC Filing  
5/14/2014Jeffrey WalshCOOSell1,500$20.03$30,045.00View SEC Filing  
5/12/2014Jeffrey WalshCOOSell4,500$18.93$85,185.00View SEC Filing  
5/1/2014David DavidsonInsiderSell4,000$19.85$79,400.00View SEC Filing  
5/1/2014Nick LeschlyCEOSell5,000$20.07$100,350.00304,318View SEC Filing  
4/10/2014Jeffrey WalshCOOSell6,000$21.29$127,740.00View SEC Filing  
1/22/2014Linda BainVPSell2,500$25.11$62,775.00View SEC Filing  
1/17/2014Robert TepperDirectorSell307,000$22.43$6,886,010.00View SEC Filing  
1/16/2014Mitchell FinerInsiderSell10,000$23.52$235,200.00View SEC Filing  
1/14/2014Robert TepperDirectorSell340,000$21.90$7,446,000.00View SEC Filing  
1/10/2014Jeffrey WalshCOOSell6,000$21.98$131,880.00View SEC Filing  
1/3/2014David DavidsonInsiderSell15,000$20.88$313,200.00View SEC Filing  
1/3/2014Linda BainVPSell5,000$20.89$104,450.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

bluebird bio (NASDAQ BLUE) News Headlines

Source:
DateHeadline
Cantor Fitzgerald Lowers bluebird bio (BLUE) Price Target to $113.00Cantor Fitzgerald Lowers bluebird bio (BLUE) Price Target to $113.00
www.americanbankingnews.com - February 25 at 1:50 PM
Aperio Group LLC Boosts Holdings in bluebird bio Inc (BLUE)Aperio Group LLC Boosts Holdings in bluebird bio Inc (BLUE)
www.americanbankingnews.com - February 25 at 4:14 AM
Top Analyst Upgrades and Downgrades: Alkermes, ArQule, Bluebird Bio, Cognizant, Ecolab, KLA-Tencor, Pandora ... - 24/7 Wall St.Top Analyst Upgrades and Downgrades: Alkermes, ArQule, Bluebird Bio, Cognizant, Ecolab, KLA-Tencor, Pandora ... - 24/7 Wall St.
247wallst.com - February 24 at 3:42 PM
Capital Analysts LLC Acquires Shares of 6,149 bluebird bio Inc (BLUE)Capital Analysts LLC Acquires Shares of 6,149 bluebird bio Inc (BLUE)
www.americanbankingnews.com - February 24 at 3:12 PM
California Public Employees Retirement System Acquires 9,946 Shares of bluebird bio Inc (BLUE)California Public Employees Retirement System Acquires 9,946 Shares of bluebird bio Inc (BLUE)
www.americanbankingnews.com - February 24 at 5:12 AM
bluebird bio Inc (BLUE) Expected to Earn FY2022 Earnings of $4.90 Per Sharebluebird bio Inc (BLUE) Expected to Earn FY2022 Earnings of $4.90 Per Share
www.americanbankingnews.com - February 23 at 5:28 PM
Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma BidStanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid
www.msn.com - February 23 at 10:47 AM
Bank of America Increases bluebird bio (BLUE) Price Target to $218.00Bank of America Increases bluebird bio (BLUE) Price Target to $218.00
www.americanbankingnews.com - February 22 at 9:10 PM
Maxim Group Reiterates "Hold" Rating for bluebird bio (BLUE)Maxim Group Reiterates "Hold" Rating for bluebird bio (BLUE)
www.americanbankingnews.com - February 22 at 5:02 PM
bluebird bio Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress - Business Wire (press release)bluebird bio Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress - Business Wire (press release)
www.businesswire.com - February 22 at 3:46 PM
bluebird bio (BLUE) Price Target Increased to $222.00 by Analysts at BMO Capital Marketsbluebird bio (BLUE) Price Target Increased to $222.00 by Analysts at BMO Capital Markets
www.americanbankingnews.com - February 22 at 3:20 PM
bluebird bio Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progressbluebird bio Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress
finance.yahoo.com - February 22 at 10:27 AM
bluebird bio (BLUE) Given Market Perform Rating at Sanford C. Bernsteinbluebird bio (BLUE) Given Market Perform Rating at Sanford C. Bernstein
www.americanbankingnews.com - February 22 at 9:56 AM
bluebird bio (BLUE) Issues  Earnings Results, Misses Expectations By $0.84 EPSbluebird bio (BLUE) Issues Earnings Results, Misses Expectations By $0.84 EPS
www.americanbankingnews.com - February 21 at 11:08 PM
bluebird bio (BLUE) Stock Rating Reaffirmed by Cantor Fitzgeraldbluebird bio (BLUE) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - February 21 at 8:16 PM
How Celgene Hopes to Cash In on CAR-THow Celgene Hopes to Cash In on CAR-T
finance.yahoo.com - February 17 at 3:45 PM
bluebird bio Appoints Alison Finger as Chief Commercial Officer ... - Business Wire (press release)bluebird bio Appoints Alison Finger as Chief Commercial Officer ... - Business Wire (press release)
www.businesswire.com - February 14 at 3:19 PM
bluebird bio Appoints Alison Finger as Chief Commercial Officerbluebird bio Appoints Alison Finger as Chief Commercial Officer
finance.yahoo.com - February 14 at 3:19 PM
bluebird bio (BLUE) to Release Quarterly Earnings on Tuesdaybluebird bio (BLUE) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 13 at 3:14 AM
bluebird bio Inc (BLUE) Given Consensus Rating of "Hold" by Brokeragesbluebird bio Inc (BLUE) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 10 at 11:40 AM
Heres Why bluebird bio Soared 15% in January -- The Motley Fool - Motley FoolHere's Why bluebird bio Soared 15% in January -- The Motley Fool - Motley Fool
www.fool.com - February 7 at 5:43 AM
Here's Why bluebird bio Soared 15% in JanuaryHere's Why bluebird bio Soared 15% in January
finance.yahoo.com - February 7 at 5:42 AM
Form 4 bluebird bio, Inc. For: Feb 01 Filed by: Davidson David - StreetInsider.comForm 4 bluebird bio, Inc. For: Feb 01 Filed by: Davidson David - StreetInsider.com
www.streetinsider.com - February 6 at 3:18 PM
David Davidson Sells 4,000 Shares of bluebird bio Inc (BLUE) StockDavid Davidson Sells 4,000 Shares of bluebird bio Inc (BLUE) Stock
www.americanbankingnews.com - February 5 at 6:44 PM
Here's Why Global Blood Therapeutics Inc. Soared 47.1% in JanuaryHere's Why Global Blood Therapeutics Inc. Soared 47.1% in January
finance.yahoo.com - February 5 at 3:17 PM
bluebird bio to Present at LEERINK Partners Global Healthcare Conference - Business Wire (press release)bluebird bio to Present at LEERINK Partners Global Healthcare Conference - Business Wire (press release)
www.businesswire.com - February 2 at 3:18 PM
Cell Therapy Market Could Boost Celgene’s Long-Term GrowthCell Therapy Market Could Boost Celgene’s Long-Term Growth
finance.yahoo.com - February 2 at 3:18 PM
bluebird bio to Present at LEERINK Partners Global Healthcare Conferencebluebird bio to Present at LEERINK Partners Global Healthcare Conference
finance.yahoo.com - February 2 at 3:18 PM
Insider Selling: bluebird bio Inc (BLUE) Insider Sells 25,000 Shares of StockInsider Selling: bluebird bio Inc (BLUE) Insider Sells 25,000 Shares of Stock
www.americanbankingnews.com - February 1 at 6:10 PM
bluebird bio Inc (BLUE) COO Sells $3,381,798.42 in Stockbluebird bio Inc (BLUE) COO Sells $3,381,798.42 in Stock
www.americanbankingnews.com - February 1 at 6:10 PM
Canaccord Genuity Reiterates Buy Rating for bluebird bio (BLUE)Canaccord Genuity Reiterates Buy Rating for bluebird bio (BLUE)
www.americanbankingnews.com - February 1 at 4:58 PM
$7.20 Million in Sales Expected for bluebird bio Inc (BLUE) This Quarter$7.20 Million in Sales Expected for bluebird bio Inc (BLUE) This Quarter
www.americanbankingnews.com - February 1 at 1:48 AM
Celgene Looking Good With Plans for More GrowthCelgene Looking Good With Plans for More Growth
finance.yahoo.com - January 30 at 3:17 PM
bluebird bio Inc (BLUE) Expected to Earn FY2017 Earnings of ($6.86) Per Sharebluebird bio Inc (BLUE) Expected to Earn FY2017 Earnings of ($6.86) Per Share
www.americanbankingnews.com - January 29 at 1:26 AM
Leerink Swann Lowers bluebird bio (BLUE) to Market PerformLeerink Swann Lowers bluebird bio (BLUE) to Market Perform
www.americanbankingnews.com - January 27 at 7:40 PM
bluebird bio (BLUE) Rating Increased to Strong-Buy at BidaskClubbluebird bio (BLUE) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - January 27 at 11:02 AM
First Week of March 16th Options Trading For bluebird bio (BLUE) - NasdaqFirst Week of March 16th Options Trading For bluebird bio (BLUE) - Nasdaq
www.nasdaq.com - January 26 at 3:17 PM
Analysts Take Action on Abbott and Bluebird BioAnalysts Take Action on Abbott and Bluebird Bio
finance.yahoo.com - January 26 at 3:17 PM
bluebird bio Inc Forecasted to Earn Q1 2018 Earnings of ($1.67) Per Share (BLUE)bluebird bio Inc Forecasted to Earn Q1 2018 Earnings of ($1.67) Per Share (BLUE)
www.americanbankingnews.com - January 26 at 7:52 AM
Leerink: Bluebird Bios Catalysts Are Priced In - BenzingaLeerink: Bluebird Bio's Catalysts Are Priced In - Benzinga
www.benzinga.com - January 25 at 3:18 PM
Leerink: Bluebird Bios Catalysts Are Priced InLeerink: Bluebird Bio's Catalysts Are Priced In
finance.yahoo.com - January 25 at 3:18 PM
Behind Celgene’s Strategy in the Juno Therapeutics AcquisitionBehind Celgene’s Strategy in the Juno Therapeutics Acquisition
finance.yahoo.com - January 24 at 3:19 PM
Bluebird Up on Buyout Speculation After Celgene/Juno DealBluebird Up on Buyout Speculation After Celgene/Juno Deal
finance.yahoo.com - January 23 at 3:20 PM
Bluebird Bio Shouldnt Be Blue - BloombergBluebird Bio Shouldn't Be Blue - Bloomberg
www.bloomberg.com - January 22 at 3:21 PM
Bluebird Bio Shouldnt Be BlueBluebird Bio Shouldn't Be Blue
finance.yahoo.com - January 22 at 3:21 PM
Why bluebird bio Is Soaring 11.9% TodayWhy bluebird bio Is Soaring 11.9% Today
finance.yahoo.com - January 22 at 3:21 PM
bluebird bio (BLUE) Soars: Stock Adds 7.3% in Sessionbluebird bio (BLUE) Soars: Stock Adds 7.3% in Session
www.zacks.com - January 18 at 10:44 AM
Juno Therapeutics Surges on Report of Celgene Deal TalksJuno Therapeutics Surges on Report of Celgene Deal Talks
www.msn.com - January 17 at 9:40 AM
Could Little Known Orgenesis (ORGS) Become A Dominant Player in The Multi Billion Dollar Cell Therapy Market?Could Little Known Orgenesis (ORGS) Become A Dominant Player in The Multi Billion Dollar Cell Therapy Market?
finance.yahoo.com - January 17 at 9:40 AM
bluebird bio, Inc. (BLUE) Receives Average Rating of "Hold" from Brokeragesbluebird bio, Inc. (BLUE) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 16 at 12:40 PM

SEC Filings

bluebird bio (NASDAQ:BLUE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

bluebird bio (NASDAQ:BLUE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

bluebird bio (NASDAQ BLUE) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.